These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 10233369)

  • 1. Risk of venous thromboembolism associated with the common hereditary haemochromatosis Hfe gene (C282Y) mutation.
    Brown K; Luddington R; Taylor SA; Lillicrap DP; Baglin TP
    Br J Haematol; 1999 Apr; 105(1):95-7. PubMed ID: 10233369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism.
    Emmerich J; Rosendaal FR; Cattaneo M; Margaglione M; De Stefano V; Cumming T; Arruda V; Hillarp A; Reny JL
    Thromb Haemost; 2001 Sep; 86(3):809-16. PubMed ID: 11583312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor V Leiden and the common haemochromatosis mutation HFE C282Y: is there an association in familial venous thromboembolic disease?
    MacLean RM; Feeney GP; Bowley SJ; Bowen DJ; Worwood M; Collins PW
    Br J Haematol; 1999 Oct; 107(1):210-2. PubMed ID: 10520044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives?
    Schambeck CM; Schwender S; Haubitz I; Geisen UE; Grossmann RE; Keller F
    Thromb Haemost; 1997 Dec; 78(6):1480-3. PubMed ID: 9423798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prevalence of factor V Leiden as a risk factor for venous thromboembolism in the population of North-Western Greece.
    Ioannou HV; Mitsis M; Eleftheriou A; Matsagas M; Nousias V; Rigopoulos C; Vartholomatos G; Kappas AM
    Int Angiol; 2000 Dec; 19(4):314-8. PubMed ID: 11305729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of venous thrombosis in carriers of the prothrombin G20210A variant and factor V Leiden and their interaction with oral contraceptives.
    Aznar J; Vayá A; Estellés A; Mira Y; Seguí R; Villa P; Ferrando F; Falcó C; Corella D; España F
    Haematologica; 2000 Dec; 85(12):1271-6. PubMed ID: 11114134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of 20210 A allele of the prothrombin gene in venous thromboembolism patients.
    Leroyer C; Mercier B; Oger E; Chenu E; Abgrall JF; Férec C; Mottier D
    Thromb Haemost; 1998 Jul; 80(1):49-51. PubMed ID: 9684784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interrelation of hyperhomocysteinemia and inherited risk factors for venous thromboembolism. Results from the E.D.I.TH. study: a hospital-based case-control study.
    Oger E; Lacut K; Le Gal G; Couturaud F; Abalain JH; Mercier B; Mottier D;
    Thromb Res; 2007; 120(2):207-14. PubMed ID: 17126889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The factor V R2 allele: risk of venous thromboembolism, factor V levels and resistance to activated protein C.
    Luddington R; Jackson A; Pannerselvam S; Brown K; Baglin T
    Thromb Haemost; 2000 Feb; 83(2):204-8. PubMed ID: 10739373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and association of the factor V Leiden and prothrombin G20210A in healthy subjects and patients with venous thromboembolism.
    Coen D; Zadro R; Honović L; Banfić L; Stavljenić Rukavina A
    Croat Med J; 2001 Aug; 42(4):488-92. PubMed ID: 11471205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombin generation and D-dimer concentrations in a patient cohort investigated for venous thromboembolism. Relations to venous thrombosis, factor V Leiden and prothrombin G20210A. The LIST study.
    Chaireti R; Jennersjö C; Lindahl TL
    Thromb Res; 2009 Jun; 124(2):178-84. PubMed ID: 19232683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor V Leiden and prothrombin 20210 G-A mutations in controls and in patients with thromboembolic events during pregnancy or the puerperium.
    Yilmazer M; Kurtay G; Sonmezer M; Akar N
    Arch Gynecol Obstet; 2003 Oct; 268(4):304-8. PubMed ID: 14504875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factor V gene A4070G mutation and the risk of cerebral veno-sinus thrombosis occurring during puerperium.
    Dindagur N; Kruthika-Vinod TP; Christopher R
    Thromb Res; 2007; 119(4):497-500. PubMed ID: 16781765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High frequency of factor V Leiden in surgical patients with symptomatic venous thromboembolism despite prophylaxis.
    Baba-Ahmed M; Le Gal G; Couturaud F; Lacut K; Oger E; Leroyer C
    Thromb Haemost; 2007 Feb; 97(2):171-5. PubMed ID: 17264942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factor V Leiden mutation and the risk of venous thromboembolism in pregnant women.
    Tormene D; Simioni P; Prandoni P; Luni S; Zerbinati P; Sartor D; Franz F; Girolami A
    Haematologica; 2001 Dec; 86(12):1305-9. PubMed ID: 11726323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of factor VIII/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutation.
    De Mitrio V; Marino R; Scaraggi FA; Di Bari L; Giannoccaro F; Petronelli M; Ranieri P; Tannoia N; Schiraldi O
    Blood Coagul Fibrinolysis; 1999 Oct; 10(7):409-16. PubMed ID: 10695766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AB0 blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms.
    Miñano A; Ordóñez A; España F; González-Porras JR; Lecumberri R; Fontcuberta J; Llamas P; Marín F; Estellés A; Alberca I; Vicente V; Corral J
    Haematologica; 2008 May; 93(5):729-34. PubMed ID: 18387978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-segregation of thrombophilic disorders in factor V Leiden carriers; the contributions of factor VIII, factor XI, thrombin activatable fibrinolysis inhibitor and lipoprotein(a) to the absolute risk of venous thromboembolism.
    Libourel EJ; Bank I; Meinardi JR; Baljé -Volkers CP; Hamulyak K; Middeldorp S; Koopman MM; van Pampus EC; Prins MH; Büller HR; van der Meer J
    Haematologica; 2002 Oct; 87(10):1068-73. PubMed ID: 12368162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation.
    Lindmarker P; Schulman S; Sten-Linder M; Wiman B; Egberg N; Johnsson H
    Thromb Haemost; 1999 May; 81(5):684-9. PubMed ID: 10365737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of recurrent venous thrombosis in patients with G20210A mutation in the prothrombin gene or factor V Leiden mutation.
    González-Porras JR; García-Sanz R; Alberca I; López ML; Balanzategui A; Gutierrez O; Lozano F; San Miguel J
    Blood Coagul Fibrinolysis; 2006 Jan; 17(1):23-8. PubMed ID: 16607075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.